Brind.
  1. Cytokinetics' drug is under FDA review, with clinical data presented at a congress in Madrid, Spain.

Cytokinetics developed and tested Aficamten, finding it superior to Metoprolol and calling into question reliance on beta-blockers.

1 report, 1 independent Updated Aug 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Cytokinetics developed and tested Aficamten, finding it superior to Metoprolol and calling into question reliance on beta-blockers.

Who's involved

What this event is mainly about
Cytokinetics

Keep exploring

Part of

Cytokinetics' drug is under FDA review, with clinical data presented at a congress in Madrid, Spain. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireCytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine Positive Trial Demonstrates Su